(1 - 19 from 26
)
World Pharma News | Merck Receives Approval from FDA for ...
www.worldpharmanews.com
help physicians help their patients, and we look forward to discussing these new uses for SAPHRIS with the mental health community," said David Michelson, M.D., vice president of Neuroscience Clinical Research, Merck.
FDA: Long-term studies before approving Meds? - Schizophrenia.com
www.schizophrenia.com
That has implication for patients," David Michelson, executive director for neuroscience medical research at Eli Lilly, said. The change likely would not increase costs for the industry by too much, Michelson added. An FDA ...
New Migraine Drug Telcagepant – Not Dead Yet
headacheandmigrainenews.com
However, Dr. David Michelson, vice president of clinical neurosciences, said Merck is still committed to this type of research: "Merck believes that the blocking of CGRP receptors remains an exciting pathway to address the ...
sorted by relevance / date